Chemokines: agents for the immunotherapy of cancer? (original) (raw)

• Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60–66 (1996).
  Article CAS PubMed Google Scholar
• Homey, B. & Zlotnik, A. Chemokines in allergy. Curr. Opin. Immunol. 11, 626–634 (1999).
  CAS PubMed Google Scholar
• Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121–127 (2000).Introduces the new systematic classification for chemokines and describes their role in immunity.
  CAS PubMed Google Scholar
• Caux, C. et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22, 345–369 (2000).Describes chemokine receptor expression of distinct dendritic cell subsets, and their responsiveness and role in dendritic cell transport.
  CAS PubMed Google Scholar
• Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23–33 (1999).
  Article CAS PubMed Google Scholar
• Homey, B. et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J. Immunol. 164, 3465–3470 (2000).
  CAS PubMed Google Scholar
• Morales, J. et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl Acad. Sci. USA 96, 14470–14475 (1999).
  CAS PubMed PubMed Central Google Scholar
• Campbell, J. J. et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400, 776–780 (1999).
  CAS PubMed Google Scholar
• Campbell, D. J. & Butcher, E. C. Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. 195, 135–141 (2002).
  CAS PubMed PubMed Central Google Scholar
• Nanki, T. et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 165, 6590–6598 (2000).
  CAS PubMed Google Scholar
• Taub, D. D., Sayers, T. J., Carter, C. R. & Ortaldo, J. R. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155, 3877–3888 (1995).
  CAS PubMed Google Scholar
• Suzuki, Y., Rahman, M. & Mitsuya, H. Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells. J. Immunol. 167, 3064–3073 (2001).
  CAS PubMed Google Scholar
• Bernardini, G. et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 96, 4039–4045 (2000).
  CAS PubMed Google Scholar
• Gupta, S. K., Lysko, P. G., Pillarisetti, K., Ohlstein, E. & Stadel, J. M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 273, 4282–4287 (1998).
  CAS PubMed Google Scholar
• Salcedo, R. et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am. J. Pathol. 154, 1125–1135 (1999).
  CAS PubMed PubMed Central Google Scholar
• Salcedo, R. et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J. Immunol. 166, 7571–7578 (2001).
  CAS PubMed Google Scholar
• Kleeff, J. et al. Detection and localization of Mip-3alpha/ LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650–657 (1999).
  CAS PubMed Google Scholar
• Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).
  CAS PubMed Google Scholar
• Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G. & Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961–4965 (2001).References 18 and 19 show that tumour cells express functionally active chemokine receptors on their cell surface and provide evidence for the role for chemokine receptors in tumour cell migration and metastasis.
  CAS PubMed Google Scholar
• Schadendorf, D. et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 2667–2675 (1993).
  CAS PubMed Google Scholar
• Miyamoto, M. et al. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol. Immunother. 47, 47–57 (1998).
  CAS PubMed Google Scholar
• Brew, R. et al. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12, 78–85 (2000).
  CAS PubMed Google Scholar
• Venkatakrishnan, G., Salgia, R. & Groopman, J. E. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem. 275, 6868–6875 (2000).
  CAS PubMed Google Scholar
• Balentien, E., Mufson, B. E., Shattuck, R. L., Derynck, R. & Richmond, A. Effects of MGSA/GROα on melanocyte transformation. Oncogene 6, 1115–1124 (1991).
  CAS PubMed Google Scholar
• Owen, J. D. et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine β and γ proteins. Int. J. Cancer 73, 94–103 (1997).
  CAS PubMed Google Scholar
• Arenberg, D. A. et al. Epithelial–neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102, 465–472 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ahuja, S. K. & Murphy, P. M. The CXC chemokines growth-regulated oncogene (GRO)α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271, 20545–20550 (1996).
  CAS PubMed Google Scholar
• Belperio, J. A. et al. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68, 1–8 (2000).
  CAS PubMed Google Scholar
• Strieter, R. M. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348–27357 (1995).
  CAS PubMed Google Scholar
• Inoue, K. et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874–4884 (2000).
  CAS PubMed Google Scholar
• Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D. & Fidler, I. J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54, 3242–3247 (1994).
  CAS PubMed Google Scholar
• Singh, R. K., Varney, M. L., Bucana, C. D. & Johansson, S. L. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res. 9, 383–387 (1999).
  CAS PubMed Google Scholar
• Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001).
  CAS PubMed Google Scholar
• Zeelenberg, I. S., Ruuls-Van Stalle, L. & Roos, E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. J. Clin. Invest. 108, 269–277 (2001).
  CAS PubMed PubMed Central Google Scholar
• Murphy, P. M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345, 833–835 (2001).
  CAS PubMed Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).
  CAS PubMed PubMed Central Google Scholar
• Asher, A. L. et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227–3234 (1991).
  CAS PubMed Google Scholar
• Tahara, H. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182–189 (1994).
  CAS PubMed Google Scholar
• Wang, J. M., Shen, W., Chertov, O., van Damme, J. & Oppenheimer, J. J. in Chemokines and Cancer (ed. Rollins, B. J.) 129–141 (Humana, Totowa, New Jersey, 1999).
  Google Scholar
• Laning, J., Kawasaki, H., Tanaka, E., Luo, Y. & Dorf, M. E. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153, 4625–4635 (1994).
  CAS PubMed Google Scholar
• Hirose, K. et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72, 708–714 (1995).
  CAS PubMed PubMed Central Google Scholar
• Nakashima, E. et al. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13, 1896–1901 (1996).
  CAS PubMed Google Scholar
• Mule, J. J. et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7, 1545–1553 (1996).
  CAS PubMed Google Scholar
• Giovarelli, M. et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164, 3200–3206 (2000).
  CAS PubMed Google Scholar
• Braun, S. E. et al. The CC chemokine CK β-11/MIP-3 β/ELC/ Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164, 4025–4031 (2000).
  CAS PubMed Google Scholar
• Fushimi, T., Kojima, A., Moore, M. A. & Crystal, R. G. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383–1393 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kirk, C. J. et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61, 2062–2070 (2001).Shows the efficacy of chemokine (CCL21)-transfected dendritic cells to induce the recruitment of leukocytes in vivo and to mediate the induction of antitumour immunity.
  CAS PubMed Google Scholar
• Sharma, S. et al. Secondary lymphoid tissue chemokine mediates T-cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558–4563 (2000).
  CAS PubMed Google Scholar
• Vicari, A. P. et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165, 1992–2000 (2000).
  CAS PubMed Google Scholar
• Luster, A. D. & Leder, P. IP-10, a-C–X–C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178, 1057–1065 (1993).
  CAS PubMed Google Scholar
• Cairns, C. M. et al. Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J. Immunol. 167, 57–65 (2001).
  CAS PubMed Google Scholar
• Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).Reviews recent findings using dendritic-cell-based immunotherapy and gives an outlook for future directions.
  CAS PubMed Google Scholar
• Greten, T. F. & Jaffee, E. M. Cancer vaccines. J. Clin. Oncol. 17, 1047–1060 (1999).
  CAS PubMed Google Scholar
• Banchereau, J., Schuler-Thurner, B., Palucka, A. K. & Schuler, G. Dendritic cells as vectors for therapy. Cell 106, 271–274 (2001).
  CAS PubMed Google Scholar
• Nagira, M. et al. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. Eur. J. Immunol. 28, 1516–1523 (1998).
  CAS PubMed Google Scholar
• Kim, C. H. et al. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC, are chemoattractants for CD56+CD16− NK cells and late stage lymphoid progenitors. Cell. Immunol. 193, 226–235 (1999).
  CAS PubMed Google Scholar
• Hedrick, J. A. & Zlotnik, A. Identification and characterization of a novel βchemokine containing six conserved cysteines. J. Immunol. 159, 1589–1593 (1997).
  CAS PubMed Google Scholar
• Kelner, G. S. et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266, 1395–1399 (1994).
  CAS PubMed Google Scholar
• Kennedy, J. et al. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 155, 203–209 (1995).
  CAS PubMed Google Scholar
• Cao, X. et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161, 6238–6244 (1998).
  CAS PubMed Google Scholar
• Dilloo, D. et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med. 2, 1090–1095 (1996).
  CAS PubMed Google Scholar
• Emtage, P. C. et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10, 697–709 (1999).
  CAS PubMed Google Scholar
• Ma, X., Aste-Amezaga, M., Gri, G., Gerosa, F. & Trinchieri, G. Immunomodulatory functions and molecular regulation of IL-12. Chem. Immunol. 68, 1–22 (1997).
  CAS PubMed Google Scholar
• Trinchieri, G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83–243 (1998).
  CAS PubMed Google Scholar
• Voest, E. E. et al. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581–586 (1995).
  CAS PubMed Google Scholar
• Narvaiza, I. et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164, 3112–3122 (2000).
  CAS PubMed Google Scholar
• Palmer, K., Hitt, M., Emtage, P. C., Gyorffy, S. & Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8, 282–290 (2001).
  CAS PubMed Google Scholar
• Ruehlmann, J. M. et al. MIG (CXCL9) chemokine gene therapy combines with antibody–cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61, 8498–8503 (2001).
  CAS PubMed Google Scholar
• Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17, 253–258 (1999).Shows the efficacy of fusion proteins that combines a chemokine with tumour antigen to attract leukocytes in vivo and to induce protective antitumour immunity.
  CAS PubMed Google Scholar
• Tazi, A. et al. Evidence that granulocyte–macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J. Clin. Invest. 91, 566–576 (1993).
  CAS PubMed PubMed Central Google Scholar
• Maas, R. A., Dullens, H. F. & Den Otter, W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141–148 (1993).
  CAS PubMed Google Scholar
• Nomura, T., Hasegawa, H., Kohno, M., Sasaki, M. & Fujita, S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1α chemokine genes. Int. J. Cancer 91, 597–606 (2001).Describes the enhanced efficacy of combining chemokines together with both T-cell (IL-2)- and dendritic-cell (GM-CSF)-activating cytokines for the immunotherapy of experimental tumours.
  CAS PubMed Google Scholar
• Morse, M. A., Clay, T. M., Hobeika, A. C., Mosca, P. J. & Lyerly, H. K. Surrogate markers of response to cancer immunotherapy. Expert Opin. Biol. Ther. 1, 153–158 (2001).
  CAS PubMed Google Scholar
• Glennie, M. J. & Johnson, P. W. Clinical trials of antibody therapy. Immunol. Today 21, 403–410 (2000).
  CAS PubMed Google Scholar
• Harjunpaa, A., Junnikkala, S. & Meri, S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51, 634–641 (2000).
  CAS PubMed Google Scholar
• Agha-Mohammadi, S. & Lotze, M. T. RegulaTable systems: applications in gene therapy and replicating viruses. J. Clin. Invest. 105, 1177–1183 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kirkwood, J. M. et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18, 2444–2458 (2000).
  CAS PubMed Google Scholar
• Jager, D., Jager, E. & Knuth, A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54, 669–674 (2001).
  CAS PubMed PubMed Central Google Scholar
• Ockert, D., Schmitz, M., Hampl, M. & Rieber, E. P. Advances in cancer immunotherapy. Immunol. Today 20, 63–65 (1999).
  CAS PubMed Google Scholar
• Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).The authors review the links between cancer and inflammation. They propose that the inflammatory cells and cytokines that are found in tumours contribute to tumour growth, progression and immunosuppression, rather than to mount an effective host antitumour response.
  CAS PubMed Google Scholar
• Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339–1346 (2001).
  CAS PubMed Google Scholar
• Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545–1552 (2000).
  CAS PubMed PubMed Central Google Scholar
• Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000).
  CAS PubMed Google Scholar
• Bottazzi, B., Walter, S., Govoni, D., Colotta, F. & Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280–1285 (1992).
  CAS PubMed Google Scholar
• Huang, S. et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother. 39, 231–238 (1994).
  CAS PubMed Google Scholar
• Nakashima, E. et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res. 12, 1598–1604 (1995).
  CAS PubMed Google Scholar